2024-03-28T09:14:58Z
http://ir.lib.uwo.ca/do/oai/
oai:ir.lib.uwo.ca:psychiatrypres-1009
2009-07-03T00:18:43Z
publication:rwkex
publication:psychiatrypres
publication:epidem
publication:epidempres
publication:faculties
publication:rwkex_presentationslidedecks
publication:psychiatry
Outcome in Schizophrenia: How Good Is "Good Outcome" Schizophrenia in Long-term in Developing Countries
Srivastava, Amresh
Thakar, Meghan
Shah, Nilesh
Stitt, Larry
Presentation
2008-09-01T07:00:00Z
schizophrenia
Mumbai
Psychiatry and Psychology
Presentation at the XIV World Congress of Psychiatry in Prague, Czech Republic on Sept. 20-25, 2008.
https://ir.lib.uwo.ca/psychiatrypres/9
oai:ir.lib.uwo.ca:psychiatrypres-1015
2009-07-18T01:37:17Z
publication:rwkex
publication:psychiatrypres
publication:epidem
publication:epidempres
publication:faculties
publication:rwkex_presentationslidedecks
publication:psychiatry
Differential Characteristics of “Good Outcome Schizophrenia” in a Long-Term Ten Years Study, Mumbai, India
Srivastava, Amresh
Thakar, Meghan
Shah, Nilesh
Stitt, Larry
Presentation
2008-09-21T07:00:00Z
schizophrenia
Mumbai
Psychiatry and Psychology
Presentation at World Congress of Psychiatry (Section Symposia of Schizophrenia) in Prague, Czech Republic on Sept. 21, 2008. It is about reflecting outcome in the metro culture of Mumbai (the world's fifth largest city).
https://ir.lib.uwo.ca/psychiatrypres/15
oai:ir.lib.uwo.ca:psychiatrypres-1026
2009-09-28T01:06:39Z
publication:rwkex
publication:psychiatrypres
publication:epidem
publication:epidempres
publication:faculties
publication:rwkex_presentationslidedecks
publication:psychiatry
First Episode Is the Best Episode: Lessons and Limitations in Duration of Untreated Psychosis (DUP) and Outcome in Schizophrenia
Srivastava, Amresh
Stitt, Larry
Thakar, Meghana
Chinnasamy, Gurusamy
Shah, Nilesh
Presentation
2009-01-01T08:00:00Z
duration of untreated psychosis
schizophrenia
Psychiatry and Psychology
Background: Early intervention in psychosis is an opportunity. Research ahs shown that if any thing community members can do to prevent psychosis is to report early. This has opened newer vistas for understanding the complexity of brain and behaviour in schizophrenia. At the same time it has raised the bar of expectations regarding its correlation to outcome. It finally narrows down to meaningful public campaign for awareness, which will decide success of research to clinics in schizophrenia management. Duration of untreated psychosis (DUP) has emerged as a reliable predictor of outcome and provides credence to development of early intervention services. It is not quite clear if DUP works in isolation and what other factors along with DUP would determine outcome long-term outcome of schizophrenia is multifactorial in nature. The present study examines effect of DUP on outcome of schizophrenia
Method: we conducted a ten years follow up study of first episode hospitalized DSM III-R schizophrenia and correlated multiple outcome criteria with DUP at Mumbai. We carefully determined onset of psychosis using criteria for appearance of positive symptoms, negative symptoms or significant social decline. Data was analyzed using SAS.
Results: we analyzed 101 patients available at ten years. We found that mean DUP was higher for group, which showed Clinical recovery on GCIS [14.0(SD=8.0) months for recovered & 10.8 (SD=5.7) months in nonrecovered group p=0.091]. There is a significant difference in favour of DUP≤6 months in terms of subscales of PANSS; However DUP was not found to be significantly associated with the end point parameters of good clinical or social outcome.
Conclusion: We find that DUP is just one factor in determinants of outcome. Several other psychopathological & phenomenological factors collectively play a role in determining outcome. Future research needs to be directed towards combination of determinants of outcome in early intervention of psychosis.
A presentation at the 2nd European Conference on Schizophrenia Research in Berlin, Germany on Sept. 23, 2009.
https://ir.lib.uwo.ca/psychiatrypres/27
oai:ir.lib.uwo.ca:epidempres-1001
2009-10-12T05:26:54Z
publication:medpres
publication:rwkex
publication:med
publication:epidem
publication:rwkex_researcharticles
publication:epidempres
publication:faculties
Nonsteroidal Antiinflammatory Drug Use May Be Protective to Cartilage in Osteoarthritis of the Hip and Knee
Pope, J. E.
Stevens, A.
McCrea, K.
Ouimet, J.
Presentation
2004-09-13T07:00:00Z
osteoarthritis
Arthritis Research & Therapy
Biostatistics
Epidemiology
Published in: Arthritis Res Ther, 2004, 6(Suppl 3):53. doi: 10.1186/ar1388
https://ir.lib.uwo.ca/epidempres/2
oai:ir.lib.uwo.ca:epidempres-1000
2009-10-12T05:11:12Z
publication:medpres
publication:rwkex
publication:med
publication:epidem
publication:rwkex_researcharticles
publication:epidempres
publication:faculties
Raynaud's Phenomenon Secondary to Rheumatoid Arthritis May Be Predictive of More Erosive Disease
Pope, J. E.
Al-beshri, J.
Presentation
2004-09-13T07:00:00Z
Arthritis Research & Therapy
Biostatistics
Epidemiology
Published in: Arthritis Res Ther, 2004, 6(Suppl 3):75. doi: 10.1186/ar1411
https://ir.lib.uwo.ca/epidempres/1
oai:ir.lib.uwo.ca:oncpres-1002
2009-11-07T02:52:45Z
publication:rwkex
publication:biophysicspres
publication:biophysics
publication:epidem
publication:rwkex_posterpresentations
publication:epidempres
publication:surgery
publication:faculties
publication:surgerypres
publication:onc
publication:oncpres
The Role of Radiation Therapy on Medically Inoperable Clinically Localized Non-small Cell Lung Patients: London Regional Cancer Program (LRCP) Clinical Experience
Lee, Michael
Yu, Edward
Ash, Robert
Tai, Patricia
Stitt, Larry
Rodrigues, George
Dar, Rashid
Vincent, Mark
Inculet, Richard
Malthaner, Richard
Presentation
2006-01-01T08:00:00Z
Radiation Therapy
London Regional Cancer Program
lung cancer
Epidemiology
Oncology
Surgery
Lung cancer is the most frequent cause of cancer death in both men and women in North America. In 2006, an estimated 22,700 Canadians will be diagnosed with lung cancer and 19,300 will die of it (Canadian Cancer Statistics 2006).
Approximately 15-20% of NSCLC patients present with early or localized disease.
Surgical resection of T1-2N0 NSCLC remains the treatment of choice for this population, and results in a 5-year survival rate of 50-70%.
Patients deemed medically inoperable have been treated with non-surgical therapies, such as radiation therapy(RT), while some patients have simply been observed without any tumor therapy because of their co-morbid illnesses.
Potential confounding issues in this patient population include some patients who are not referred to our Centre due to co-morbid disease, and some who are referred, but are not offered radical RT due to poor outcome expectations. In addition, patients may refuse treatment when offered.
We have reviewed thepast 19 years’ experience at LRCP inmanagement of this group of patients.
Presentation at the Canadian Association of Radiation Oncologists (CARO) Annual Scientific Meeting in Calgary, AB in 2006
https://ir.lib.uwo.ca/oncpres/3
oai:ir.lib.uwo.ca:oncpres-1004
2009-11-07T03:41:13Z
publication:rwkex
publication:biophysicspres
publication:biophysics
publication:epidem
publication:medimagingpres
publication:rwkex_researcharticles
publication:epidempres
publication:medimaging
publication:surgery
publication:faculties
publication:surgerypres
publication:onc
publication:oncpres
Is Extended Volume of External Beam Irradiation Beneficial in Post-esophagectomy High Risk Patients Receiving Combined Chemoradiation Therapy?
Yu, E.
Dar, A. R.
Ash, R.
Videtic, G.
Truong, P.
Stitt, L.
Tomiak, A.
Vincent, M.
Malthaner, R.
Craig, I.
Brecevic, E.
Kocha, W.
Inculet, R.
Lefcoe, M.
Presentation
2001-01-01T08:00:00Z
irradiation
esophageal cancer
esophagectomy
chemoradiation therapy
Bioimaging and Biomedical Optics
Oncology
Surgery
OBJECTIVE: To assess the value of extended volume irradiation with anastomotic coverage in high risk resected esophageal cancer patients.
METHOD: A retrospective study was undertaken at LRCC from 1989-1999 for high risk resected esophageal cancer patients. Adjuvant treatments consisted of 4 cycles of chemotherapy (epirubicin/fluorouracil/cisplatin or cisplatin/fluorouracil), and local regional irradiation with or without coverage of the anastomotic site. Radiation dose ranged from 45-60Gy at 1.8-2.0 Gy/fraction given with initial anterior-posterior/posterior-anterior arrangement with either extended (with anastomotic coverage) or small (without anastomotic coverage) field followed by oblique fields for boost.
RESULT: One hundred eighty-eight charts were reviewed. Seventy-two patients were eligible for post-resection chemoradiation therapy. Three patients had disease progression prior to therapy, and 69 patients were analyzed. There were 81% T3N1 and 13% T2N1. Thirty-four patients had margin involvements (radial 53%; proximal/distal 32%), 65% were adenocarcinoma and 33% were squamous carcinoma. Median followup was 23.6 months (3.4 - 78.4 months). Two year survival was 50%; 5yr 24%. Relapse rate was 62.3% and median time to relapse was 20 months. Recurrence locally to anastomosis or adjacent to anastomosis was 9/43(20.9%) with small field and 2/26(7.7%) with extended field. Of 31 patients with relapse outside anastomosis, 14/20(70%) relapsed locoregional/distal when treated with small field and 3/11(27%) relapsed locoregional/distal when treated with extended field (p=0.02). There was no excess treatment interruption or chronic gastrointestinal toxicity with extended field irradiation.
CONCLUSION: There is significant decrease in locoregional/distal relapse with use of extended field in high risk resected esophageal cancer patients.
Presentation at the Canadian Association of Radiation Oncologists (CARO) Annual Scientific Meeting in Québec City, QC in 2001
https://ir.lib.uwo.ca/oncpres/5
oai:ir.lib.uwo.ca:oncpres-1000
2009-11-07T02:14:37Z
publication:rwkex
publication:biophysicspres
publication:biophysics
publication:epidem
publication:rwkex_posterpresentations
publication:epidempres
publication:surgery
publication:faculties
publication:surgerypres
publication:onc
publication:oncpres
Post-Operative Extended Volume External Beam Radiation Therapy Is Safe for High Risk Esophageal Cancer Patients
Yu, Edward
Tai, Patricia
Younus, Jawaid
Malthaner, Richard
Stitt, Larry
Truong, Pauline
Rodrigues, George
Ash, Robert
Dar, Rashid
Tomiak, Anna
Vincent, Mark
Kocha, Walter
Dingle, Brian
Inculet, Richard
Presentation
2007-01-01T08:00:00Z
Radiation Therapy
Esophageal Cancer
Epidemiology
Oncology
Surgery
Post-operative radiation therapy (RT) (1) and post-operative chemoradiation (2) have been used for esophageal cancer patients deemed high risk for recurrence after esophagectomy.
Defining opitmal RT target volume after esophagectomy is difficult due to significant changes in patient anatomy and function.
Some radiationon cologists advocated the inclusion of the anastomotic site within the irradiation volume due to concerns for potential increased relapse risk, while others did not subscribe to this practice due to concerns for increased treatment related toxicity.
We have previously reported patient outcome benefit using extended volume RT In management with high risk esophageal cancer patients underwent esopagectomy(3).
We have performed a Phase I study to evaluate the safety of subscription to this practice.
(1). Folk et al, Surgery, 113:1993
(2). Bedard et al, Cancer, 91;2001
(3). Yu et al, Radiother & Oncol, 73;2004
Presentation at the Canadian Association of Radiation Oncologists (CARO) Annual Scientific Meeting in Toronto, ON in Oct. 2007
https://ir.lib.uwo.ca/oncpres/1
oai:ir.lib.uwo.ca:oncpres-1003
2009-11-07T03:26:33Z
publication:rwkex
publication:biophysicspres
publication:biophysics
publication:epidem
publication:rwkex_posterpresentations
publication:epidempres
publication:surgery
publication:faculties
publication:surgerypres
publication:onc
publication:oncpres
Extended vs. Small Field Irradiation in High Risk Post Esophagectomy Patients Receiving Combined Chemoradiation Therapy: A Decade Experience in Treatment of Esophageal Cancer
Yu, Edward
Tai, Patricia
Rodrigues, George
Ash, Robert
Stitt, Larry
Dar, Rashid A.
Truong, Pauline
Videtic, Gregory M.
Malthaner, Richard
Inculet, Richard
Tomiak, Anna
Younus, Jawaid
Dingle, Brian
Kocha, Walter
Vincent, Mark
Presentation
2005-01-01T08:00:00Z
irradiation
esophageal cancer
esophagectomy
chemoradiation therapy
Epidemiology
Oncology
Surgery
OBJECTIVE: To assess the impact of extended field irradiation with anastomotic coverage on local recurrence in high risk resected esophageal cancerpatients.
METHODS: From 1989-1999, high risk resected esophageal cancer cases receiving post-resection chemoradiation were reviewed. Adjuvant chemotherapy consisted of four cycles of fluorouracil-based regimens. Loco-regional irradiation with or without coverage of anastomotic site had radiation a dose range from 45-60 Gyat 1.8-2.0 Gy/fraction given with initial anterior-posterior/posterior-anterior arrangement with either extended (with anastomotic coverage), or small (without anastomotic coverage) field followed by oblique fields for boost.
RESULTS: One hundred eighty-eight charts were reviewed. Seventy-two patients were eligible for post-resection chemoradiation. Three patients had disease progression prior to therapy, and 69 patients were analyzed. The median age was 60 years (range 35-82 years) with 94% T2-3N1 and 65% were adenocarcinoma. As of January 2005 median followup was 30.5 months (range 3-142 months), the two-and five-year overall survival rates were 50% and 31%, respectively. First relapse rate after adjuvant therapy was 71% (n=49) and median time to relapse was about 30 months. Loco-regional relapse with small field was 25/35 (71.4%) and 2/14 (14.2%) with extended field (P<0.001). Recurrence locally to anastomosis or adjacent site was 10/35 (28.6%) with small field and 0/14 (0%) with extended field (P=0.04).
CONCLUSION: At a minimum of 5-year followup, there is significant decrease in loco-regional relapse with the use of extended field in high risk resected esophageal cancer patients. This important improvement trend deserves further exploration in prospective randomized clinical trials.
Presentation at the Canadian Association of Radiation Oncologists (CARO) Annual Scientific Meeting in Victoria, BC in 2005
https://ir.lib.uwo.ca/oncpres/4
oai:ir.lib.uwo.ca:oncpres-1006
2010-01-26T22:27:35Z
publication:biophysicspres
publication:rwkex
publication:rwkex_powerpointposters
publication:biophysics
publication:epidem
publication:epidempres
publication:surgery
publication:faculties
publication:surgerypres
publication:onc
publication:oncpres
What Factors Predict Outcome at Relapse after Previous Esophagectomy and Adjuvant Therapy in High-Risk Esophageal Cancer?
Yu, Edward
Tai, Patricia
Malthaner, Richard
Stitt, Larry
Rodrigues, George
Dar, Rashid
Yaremko, Brian
Younus, Jawaid
Sanatani, Michael
Vincent, Mark
Dingle, Brian
Fortin, Dalilah
Inculet, Richard
Presentation
2009-10-01T07:00:00Z
Esophagectomy
Adjuvant Therapy
Esophageal Cancer
Epidemiology
Oncology
Surgery
Management of patients who have disease relapse after completion of surgery and adjuvant chemo-radiation (CRT) is controversial.
Some oncologists would advocate intensive therapeutic intervention due to promising experience on treatment for recurrence disease while others would recommend palliative support due to the concerns for poor patient outcome post disease recurrence.
In Addition, it is not clear if patient outcome is improved post adjuvant CRT when patients at risk have resection margin involvement and if time interval to recurrence can affect patient survival post relapse.
The present study was conducted to determine what factors will affect patient outcome at relapse after previous surgery and adjuvant CRT in high-risk esophageal cancer patients
This clinical information may be useful in providing appropriate guidance for oncologists to manage esophageal cancer patients after disease relapse.
Presentation at the Canadian Association of Radiation Oncologists (CARO) Annual Scientific Meeting in Québec City in Oct. 2009
https://ir.lib.uwo.ca/oncpres/7
oai:ir.lib.uwo.ca:psychiatrypres-1033
2010-02-13T02:38:18Z
publication:rwkex
publication:psychiatrypres
publication:epidem
publication:rwkex_posterpresentations
publication:epidempres
publication:faculties
publication:psychiatry
Do Atypical Antipsychotics Differ in Determining Long-term Outcome of First Episode Schizophrenia? A Naturalistic Outcome Study in India
Srivastava, Amresh
Shah, Nilesh
Johnston, Megan
Stitt, Larry
Thakar, Meghana
Chinnasamy, Gurusamy
Mital, Anukant
Presentation
2010-01-01T08:00:00Z
Atypical Antipsychotics
Schizophrenia
India
Psychiatry and Psychology
Antipsychotic medications form the mainstream of treatment in schizophrenia. These drugs have several short term as well long term advantage. It is not known if atypical antipsychotics have the long-term effect in improving outcome and meeting expectations (1,2,3). The present study examined usage and association of antipsychotics drugs with clinical outcome a long-term naturalistic study.
A presentation at the 5th International Conference on Psychiatry held in Dhaka, Bangladesh in Jan. 2010
https://ir.lib.uwo.ca/psychiatrypres/32
oai:ir.lib.uwo.ca:psychiatrypres-1034
2010-03-16T19:00:17Z
publication:rwkex
publication:psychiatrypres
publication:epidem
publication:rwkex_posterpresentations
publication:epidempres
publication:faculties
publication:psychiatry
Predictors and Characteristics of Response and Nonresponse: A Ten Year Follow-Up of First Episode Schizophrenia in Mumbai
Shrivastava, Amresh
Shah, Nilesh
Johnston, Megan
Stitt, Larry
Thakar, Meghana
Chinnasamy, Gurusamy
Presentation
2010-01-19T08:00:00Z
schizophrenia
Mumbai
Psychiatry and Psychology
▪ It is not clearly known what predicts good long-term outcome in first episode schizophrenia and what the characteristics are that differentiate patients who do and do not show good response
▪ We attempted to find the characteristics and predictors of good out-come for patients who presented with severe psychopathology and were hospitalized in their first episode psychosis in a tertiary psychiatric hospital in the city of Mumbai
▪ 101 patients of first episode schizophrenia were assessed at hospitalization, and reassessed at ten years
▪ The data was analyzed on 13 outcome parameters for predictors and characteristics of good outcome, using the SAS system of statistical analysis
▪ 61 of 101 patients showed good outcome on the CGIS after ten years
▪ Predictors of good recovery were high baseline positive symptoms and low negative symptoms, higher anxiety-depressive symptoms, lower level of depressive symptoms, lower level of aggression, higher work performance and ability to live independently.
▪ Characteristics of non-recovered patients showed higher extra pyramidal symptoms, severe aggressive symptoms, higher frequency of disorganization symptoms at baseline and higher level of family burden at the end of the term
▪ Our study shows reasonably good outcome [61.7%] in first episode-hospitalized patients
▪ Good outcome correlated with severity of positive symptoms, level of work function and ability to live independently at baseline
A poster presentation at the Annual National Conference of the Indian Psychiatry Society in Jaipur, India in Jan. 2010
https://ir.lib.uwo.ca/psychiatrypres/33
oai:ir.lib.uwo.ca:researchday-1003
2010-04-22T23:22:00Z
publication:researchday
publication:rwkex_posterpresentations
publication:philosophy
publication:epidempres
publication:rotmanpres
publication:faculties
publication:medpres
publication:rwkex
publication:med
publication:philosophypres
publication:epidem
publication:rotman
publication:institutes
Conceptual Problems in Research Ethics
Weijer, Charles
Bioethics and Medical Ethics
Medicine and Health Sciences
Philosophy
This poster addresses these issues:<br>
• What good is medical research?<br>
• What is owed to the study subject?<br>
• When is research risk acceptable?<br>
• How should we conduct research in developing countries?<br>
• How should we conduct research involving communities?
https://ir.lib.uwo.ca/researchday/2010/Humanities/4
oai:ir.lib.uwo.ca:researchday-1004
2010-04-22T23:22:24Z
publication:researchday
publication:rwkex_posterpresentations
publication:epidempres
publication:rotmanpres
publication:faculties
publication:rwkex
publication:epidem
publication:rotman
publication:institutes
Researchers’ Views on Ethical Challenges in Healthcare Cluster-randomized Trials
McRae, Andrew
Bioethics and Medical Ethics
• Cluster-randomized trials (CRTs) commonly used in education, public health, healthcare and social sciences<br>
• Groups of individuals randomly assigned to receive one of 2 (or more) comparator interventions<br>
• Effect of interventions evaluated after collecting data from individual group members<br>
• Ethics guidelines developed for oversight of research enrolling individual subjects<br>
• Little specific guidance for ethical conduct of CRTs<br>
• Lack of guidance may lead to variability in ethics reviews between jurisdictions and over time
https://ir.lib.uwo.ca/researchday/2010/Humanities/5
oai:ir.lib.uwo.ca:philosophypres-1000
2010-05-14T23:07:08Z
publication:philosophy
publication:epidempres
publication:rotmanpres
publication:faculties
publication:rwkex_presentationslidedecks
publication:medpres
publication:rwkex
publication:med
publication:philosophypres
publication:epidem
publication:rotman
publication:institutes
Ethical Challenges in ICU Research
Weijer, Charles
Presentation
2009-10-01T07:00:00Z
Research ethics
Intensive care unit
Bioethics
Bioethics and Medical Ethics
Philosophy
Presentation at the Critical Care Canada Forum held in Toronto, ON in Oct. 2009
https://ir.lib.uwo.ca/philosophypres/2
oai:ir.lib.uwo.ca:philosophypres-1001
2010-05-09T07:20:08Z
publication:philosophy
publication:epidempres
publication:rotmanpres
publication:faculties
publication:rwkex_presentationslidedecks
publication:medpres
publication:rwkex
publication:med
publication:philosophypres
publication:epidem
publication:rotman
publication:institutes
When Can Physicians Say “No” to Families and Patients?
Weijer, Charles
Presentation
2009-10-01T07:00:00Z
Bioethics
Physician-patient relationship
Bioethics and Medical Ethics
Philosophy
Presentation at the Critical Care Canada Forum held in Toronto, ON in Oct. 2009
https://ir.lib.uwo.ca/philosophypres/1
oai:ir.lib.uwo.ca:philosophypres-1002
2011-10-14T00:48:28Z
publication:philosophy
publication:epidempres
publication:rotmanpres
publication:faculties
publication:rwkex_powerpointslides
publication:medpres
publication:rwkex
publication:med
publication:philosophypres
publication:epidem
publication:rotman
publication:institutes
Revisiting the Ethics of HIV Prevention Research in Developing Countries
Weijer, Charles
LeBlanc, Guy
Presentation
2006-08-01T07:00:00Z
Medical ethics
Bioethics
HIV
Developing countries
Bioethics and Medical Ethics
Philosophy
<p>Issues: We present key aspects of our paper, commissioned by UNAIDS in 2005, entitled, “Revisiting the ethics of HIV prevention research in developing countries.” In 2004 and 2005 we witnessed the closure or suspension of three international clinical trials testing tenofovir in the prevention of HIV infection in high risk groups due to the failure to provide free treatment to those who seroconvert during the conduct of the study. We examine critically moral claims for the provision of treatment to those who seroconvert in HIV prevention trials and ask whether it is a matter of moral obligation or moral negotiation? Description: Using the tools of philosophical and regulatory analysis we examine the moral foundations of research ethics, international regulation, and the contemporary literature in search of valid arguments in support of a moral obligation to treat. Arguments supporting the obligation to provide such treatment are found in a wide variety of documents. These claims are variously rooted in the demand to compensate for research-related injury, maximization of research benefit, justice as reciprocity, and justice as equality. Lessons learned: Our analysis reveals that there is as of yet no robust moral argument supporting a moral obligation to provide treatment to participants in HIV prevention trials who seroconvert. We argue that moral negotiation offers distinct advantages over moral obligation. Moral negotiation finds support in the principle of respect for communities that holds researchers responsible to respect communal values, protect and empower social institutions and abide by the decisions of accepted communal authorities. Recommendations: Moral negotiation, rather than moral obligation, reduces the chance of polarization of positions by inviting trial participants, sponsors, researchers and all other involved parties to the table for discussion. Moral negotiation favors middle ground solutions that fit the specific health needs and priorities of the community in question.</p>
<p>Presentation at the XVI International AIDS Conference held in Toronto, ON in August 2006</p>
https://ir.lib.uwo.ca/philosophypres/3
oai:ir.lib.uwo.ca:philosophypres-1003
2010-06-24T06:31:40Z
publication:philosophy
publication:epidempres
publication:rotmanpres
publication:faculties
publication:rwkex_powerpointslides
publication:medpres
publication:rwkex
publication:med
publication:philosophypres
publication:epidem
publication:rotman
publication:institutes
Clinical Equipoise and RCT Design
Weijer, Charles
Presentation
2000-02-01T08:00:00Z
Clinical equipoise
Randomized clinical trials
Clinical trial design
Bioethics and Medical Ethics
Philosophy
This presentation addresses these questions:<br>
• “Upon what ethical grounds may the physician offer RCT enrollment to a patient?”<br>
• Which is the preferred moral basis of the RCT?
This presentation was delivered at the Ethical Issues in Clinical Trials Conference held at the Center for Ethics and Values in the Sciences, The University of Alabama at Birmingham in Feb. 2000.<br>
Dr. Charles Weijer is currently a faculty member at The University of Western Ontario.
https://ir.lib.uwo.ca/philosophypres/4